Schering Telescope Points To 5 R&D “Stars,” But TRA Shines Brightest
Executive Summary
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on
You may also be interested in...
Priority Of Merck's Integration Of Schering Is Retaining Top R&D Talent - Kim
Merck's acquisition of Schering-Plough won't close until the fourth quarter, but the drug maker is already wading through a pipeline review to determine which research programs will get a green light as part of the combined company and which ones might get shelved
Priority Of Merck's Integration Of Schering Is Retaining Top R&D Talent - Kim
Merck's acquisition of Schering-Plough won't close until the fourth quarter, but the drug maker is already wading through a pipeline review to determine which research programs will get a green light as part of the combined company and which ones might get shelved
Priority Of Merck's Integration Of Schering Is Retaining Top R&D Talent, Kim Says
Identifying and retaining key Schering-Plough R&D personnel is a top priority once the mega-merger is complete, Merck says.